{Reference Type}: Journal Article
{Title}: Fungal-associated pneumonia in patients with hematological malignancies.
{Author}: Pineda-Benítez S;Islas-Muñoz BD;Alatorre-Fernández P;Ibanes-Gutiérrez C C;Volkow-Fernández P;Cornejo-Juárez P;
{Journal}: Indian J Med Microbiol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 24
{Factor}: 1.347
{DOI}: 10.1016/j.ijmmb.2024.100654
{Abstract}: <B>OBJECTIVE: </B>Patients with hematologic malignancies (HM) are at high risk of invasive lung fungal infections (ILFI). To describe the main characteristics, treatment, and outcomes for five years in adult patients with HM and fungal pneumonia.<BR><B>METHODS: </B>We conducted a retrospective study at Instituto Nacional de Cancerología (INCan), a referral tertiary care oncology hospital with 135 beds in Mexico City, Mexico. We included all cases of fungal pneumonia in patients with HM from January 1, 2017, to December 31, 2022. Cases were classified as proven, probable, and possible according to EORTC/MSG criteria 2021.<BR><B>RESULTS: </B>Two hundred ten patients were included; the mean age was 40 years. The most frequent HM was acute lymphoblastic leukemia (n=74) and acute myeloid leukemia (n=68). One hundred forty patients (66.7%) had severe neutropenia for a median of 16 days. All patients had a CT thorax scan; in 132 (62.9%), multiple nodules were documented. Serum galactomannan (GM) was positive in 21/192 (10.9%) and bronchoalveolar lavage in 9/36 (25%). Fifty-three patients (25.2%) died in the first month. In the multivariate analysis for mortality in the first 30 days, hypoalbuminemia, shock, possible ILFI, and inappropriate antifungal treatment were statistically associated.<BR><B>CONCLUSIONS: </B>In high-risk HM patients, CT thorax scan and GM help diagnose ILFI. An appropriate antifungal improves mortality.